International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Last updated

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is an initiative that brings together regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of pharmaceutical product development and registration. The mission of the ICH is to promote public health by achieving greater harmonisation through the development of technical Guidelines and requirements for pharmaceutical product registration. [1]

Contents

Harmonisation leads to a more rational use of human, animal and other resources, the elimination of unnecessary delay in the global development, and availability of new medicines while maintaining safeguards on quality, safety, efficacy, and regulatory obligations to protect public health. Junod notes in her 2005 treatise on Clinical Drug Trials that "Above all, the ICH has succeeded in aligning clinical trial requirements." [2]

History

In the 1980s the European Union began harmonising regulatory requirements. In 1989, Europe, Japan, and the United States began creating plans for harmonisation. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in April 1990 at a meeting in Brussels. ICH had the initial objective of coordinating the regulatory activities of the European, Japanese and United States regulatory bodies in consultation with the pharmaceutical trade associations from these regions, to discuss and agree the scientific aspects arising from product registration. [3] Since the new millennium, ICH's attention has been directed towards extending the benefits of harmonisation beyond the founding ICH regions.[ citation needed ]

In 2015, ICH underwent several reforms and changed its name to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use while becoming a legal entity in Switzerland as a non-profit association. [4] [5] The aim of these reforms was to transform ICH into a truly global initiative supported by a robust and transparent governance structure. [6] The ICH Association established an Assembly as the over-arching governing body with the aim of focusing global pharmaceutical regulatory harmonisation work in one venue that allows pharmaceutical regulatory authorities and concerned industry organisations to be more actively involved in ICH’s harmonisation work. The new Assembly met for the first time on 23 October 2015. [5]

Structure

The ICH comprises the following bodies: [7]

  1. ICH Assembly
  2. ICH Management Committee
  3. MedDRA Management Committee
  4. ICH Secretariat

The ICH Assembly brings together all Members and Observers of the ICH Association as the overarching governing body of ICH. It adopts decisions in particular on matters such as on the adoption of ICH Guidelines, admission of new Members and Observers, and the ICH Association’s work plans and budget. Member representatives appointed to the Assembly are supported by ICH Coordinators who represent each Member to the ICH Secretariat on a daily basis.[ citation needed ]

The ICH Management Committee (MC) is the body that oversees operational aspects of ICH on behalf of all Members, including administrative and financial matters and oversight of the Working Groups (WGs).[ citation needed ]

The MedDRA Management Committee (MC) has responsibility for direction of MedDRA, ICH’s standardised medical terminology. The MedDRA MC has the role of managing, supporting, and facilitating the maintenance, development, and dissemination of MedDRA. [8]

The ICH Secretariat is responsible for day-to-day management of ICH, coordinating ICH activities as well as providing support to the Assembly, the MC and Working Groups. The ICH Secretariat also provides support for the MedDRA MC. The ICH Secretariat is located in Geneva, Switzerland.[ citation needed ]

The ICH WGs are established by the Assembly when a new technical topic is accepted for harmonisation, and are charged with developing a harmonised guideline that meets the objectives outlined in the Concept Paper and Business Plan. Face-to-face meetings of the WG will normally only take place during the biannual ICH meetings. Interim reports are made at each meeting of the Assembly and made publicly available on the ICH website.

Process of Harmonisation

ICH harmonisation activities fall into 4 categories: Formal ICH Procedure, Q&A Procedure, Revision Procedure and Maintenance Procedure, depending on the activity to be undertaken. The development of a new harmonised guideline and its implementation (the formal ICH procedure) involves 5 steps: [9]

Step 1: Consensus building

The WG works to prepare a consensus draft of the Technical Document, based on the objectives set out in the Concept Paper. When consensus on the draft is reached within the WG, the technical experts of the WG will sign the Step 1 Experts sign-off sheet. The Step 1 Experts Technical Document is then submitted to the Assembly to request adoption under Step 2 of the ICH process.

Step 2a: Confirmation of consensus on the Technical Document

Step 2a is reached when the Assembly agrees, based on the report of the WG, that there is sufficient scientific consensus on the technical issues for the Technical Document to proceed to the next stage of regulatory consultation. The Assembly then endorses the Step 2a Technical Document.

Step 2b: Endorsement of draft Guideline by Regulatory Members

Step 2b is reached when the Regulatory Members of the Assembly further endorse the draft Guideline. [10]

Step 3: Regulatory consultation and discussion

Step 3 occurs in three distinct stages: regulatory consultation, discussion, and finalisation of the Step 3 Expert Draft Guideline.

Step 4: Adoption of an ICH Harmonised Guideline

Step 4 is reached when the Regulatory Members of the Assembly agree that there is sufficient scientific consensus on the draft Guideline and adopt the ICH Harmonised Guideline.

Step 5: Implementation

The ICH Harmonised Guideline moves immediately to the final step of the process that is the regulatory implementation. This step is carried out according to the same national/regional procedures that apply to other regional regulatory guidelines and requirements in the ICH regions.

Information on the regulatory action taken and implementation dates are reported back to the Assembly and published by the ICH Secretariat on the ICH website. [11]

Work products

Guidelines

The ICH topics are divided into four categories and ICH topic codes are assigned according to these categories: [11]

ICH Guidelines are lack binding force, instead implemented by regulatory members through national and regional governance. [12]

MedDRA

MedDRA is a rich and highly specific standardised medical terminology developed by ICH to facilitate sharing of regulatory information internationally for medical products used by humans. It is used for registration, documentation and safety monitoring of medical products both before and after a product has been authorised for sale. Products covered by the scope of MedDRA include pharmaceuticals, vaccines and drug-device combination products. [13]

See also

Notes

  1. Mullin Theresa (17 Nov 2017). "International Regulation of Drugs and Biological Products". In Gallin, John I.; Ognibene, Frederick P.; Lee Johnson, Laura (eds.). Principles and Practice of Clinical Research. Academic Press. p. 88.
  2. Junod, Valerie (2005). Clinical drug trials - Studying the safety and efficacy of new pharmaceuticals. (thesis for Faculté de droit de Genève) Bruxelles: Bruylant. p. 107.
  3. Teasdale, Andrew; Elder, David; Nims, Raymond W. (9 Oct 2017). ICH Quality Guidelines: An Implementation Guide. John Wiley & Sons. p. 1.
  4. ICH Makes Organizational Changes, Zachary Brennan, 26 October 2015, Regulatory Affairs Professionals Society
  5. 1 2 ICH is now International Council for Harmonisation – a Legal Swiss Entity, James Lind Institute
  6. "International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)". European Medicines Agency. 2018-09-17.
  7. Lourenco, C.; Orphanos, N.; Parker, C. (2016). "The International Council for Harmonisation : Positioning of the future with its recent reform and over 25 years of harmonisation work". Pharmaceuticals Policy and Law. 18 (1–4): 82. doi:10.3233/PPL-160434.
  8. Mullin Theresa (17 Nov 2017). "International Regulation of Drugs and Biological Products". In Gallin, John I.; Ognibene, Frederick P.; Lee Johnson, Laura (eds.). Principles and Practice of Clinical Research. Academic Press. p. 92.
  9. Van der Laan, Jan Willem; DeGeorge, Joseph (11 Feb 2013). Global Approach in Safety Testing: ICH Guidelines Explained. Springer Science & Business Media. p. 3.
  10. Lourenco, C.; Orphanos, N.; Parker, C. (2016). "The International Council for Harmonisation : Positioning of the future with its recent reform and over 25 years of harmonisation work". Pharmaceuticals Policy and Law. 18 (1–4): 86. doi:10.3233/PPL-160434.
  11. 1 2 "Welcome to the ICH Official Website". International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). 2022.
  12. van Boxtel, Chris J.; Santoso, Budiono; Edwards, Ralph (2008). Drug Benefits and Risks: International Textbook of Clinical Pharmacology. IOS Press. p. 70.
  13. "MedDRA/Work Products". Content is copied from this source, which is © ICH. Content may be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the information and material is acknowledged at all times.

Related Research Articles

<span class="mw-page-title-main">Good manufacturing practice</span> Manufacturing quality standards

Current good manufacturing practices (cGMP) are those conforming to the guidelines recommended by relevant agencies. Those agencies control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use. The rules that govern each industry may differ significantly; however, the main purpose of GMP is always to prevent harm from occurring to the end user. Additional tenets include ensuring the end product is free from contamination, that it is consistent in its manufacture, that its manufacture has been well documented, that personnel are well trained, and that the product has been checked for quality more than just at the end phase. GMP is typically ensured through the effective use of a quality management system (QMS).

A subscription-based product of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), MedDRA or Medical Dictionary for Regulatory Activities is a clinically validated international medical terminology dictionary-thesaurus used by regulatory authorities and the biopharmaceutical industry during the regulatory process, from pre-marketing to post-marketing activities, and for safety information data entry, retrieval, evaluation, and presentation. Also, it is the adverse event classification dictionary.

Pharmacovigilance, also known as drug safety, is the pharmaceutical science relating to the "collection, detection, assessment, monitoring, and prevention" of adverse effects with pharmaceutical products. The etymological roots for the word "pharmacovigilance" are: pharmakon and vigilare. As such, pharmacovigilance heavily focuses on adverse drug reactions (ADR), which are defined as any response to a drug which is noxious and unintended, including lack of efficacy. Medication errors such as overdose, and misuse and abuse of a drug as well as drug exposure during pregnancy and breastfeeding, are also of interest, even without an adverse event, because they may result in an adverse drug reaction.

<span class="mw-page-title-main">Common Technical Document</span> Internationally agreed format for drug approvals

The Common Technical Document (CTD) is a set of specifications for an application dossier for the registration of medicine, designed for use across Europe, Japan, the United States, and beyond.

<span class="mw-page-title-main">European Medicines Agency</span> Agency of the European Union

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).

Regulatory affairs (RA), is a profession that deals with an organization’s adherence to regulatory compliance.

A serious adverse event (SAE) in human drug trials is defined as any untoward medical occurrence that at any dose

  1. Results in death
  2. Is life-threatening
  3. Requires inpatient hospitalization or causes prolongation of existing hospitalization
  4. Results in persistent or significant disability/incapacity
  5. May have caused a congenital anomaly/birth defect
  6. Requires intervention to prevent permanent impairment or damage

Good clinical practice (GCP) is an international quality standard, which governments can then transpose into regulations for clinical trials involving human subjects. GCP follows the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and enforces tight guidelines on ethical aspects of clinical research.

<span class="mw-page-title-main">Council for International Organizations of Medical Sciences</span> International non-governmental medical science organization

The Council for International Organizations of Medical Sciences (CIOMS) is an international non-governmental organization of 40 international, national, and associate member groups representing the biomedical science community. It was jointly established by the World Health Organization (WHO) and United Nations Educational, Scientific and Cultural Organization (UNESCO) in 1949 as a successor to the International Medical Congress that organized 17 conferences from 1867 until the 1913 outbreak of World War One.

The electronic common technical document (eCTD) is an interface and international specification for the pharmaceutical industry to agency transfer of regulatory information. The specification is based on the Common Technical Document (CTD) format and was developed by the International Council for Harmonisation (ICH) Multidisciplinary Group 2 Expert Working Group.

In drug development and medical device development the Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product obtained during a drug trial. The IB is a document of critical importance throughout the drug development process and is updated with new information as it becomes available. The purpose of the IB is to compile data relevant to studies of the IP in human subjects gathered during preclinical and other clinical trials.

A clinical investigator involved in a clinical trial is responsible for ensuring that an investigation is conducted according to the signed investigator statement, the investigational plan, and applicable regulations; for protecting the rights, safety, and welfare of subjects under the investigator's care; and for the control of drugs under investigation. The Clinical Investigator must also meet requirements set forth by the FDA, EMA or other regulatory body. The qualifications must be outlined in a current resume and readily available for auditors.

<span class="mw-page-title-main">European Directorate for the Quality of Medicines & HealthCare</span> International organisation

The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a Directorate of the Council of Europe that traces its origins and statutes to the Convention on the Elaboration of a European Pharmacopoeia.

Safety pharmacology is a branch of pharmacology specialising in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above.

The following outline is provided as an overview of and topical guide to clinical research:

An estimand is a quantity that is to be estimated in a statistical analysis. The term is used to distinguish the target of inference from the method used to obtain an approximation of this target and the specific value obtained from a given method and dataset. For instance, a normally distributed random variable has two defining parameters, its mean and variance . A variance estimator:

In medicine, a clinical study report (CSR) on a clinical trial is a document, typically very long, providing much detail about the methods and results of a trial. A CSR is a scientific document addressing efficacy and safety, not a sales or marketing tool; its content is similar to that of a peer-reviewed academic paper. Results of trials are usually reported in a briefer academic journal paper, but methodological flaws are often glossed over in the briefer paper.

VigiBase is a World Health Organization's (WHO) global Individual Case Safety Report (ICSR) database that contains ICSRs submitted by the participating member states enrolled under WHO's international drug monitoring programme. It is the single largest drug safety data repository in the world. Since 1978, the Uppsala Monitoring Centre on behalf of WHO, have been maintaining VigiBase. Vigibase is used to obtain the information about a safety profile of a medicinal product. These data are used by pharmaceutical industries, academic institutions and regulatory authorities for statistical signal detection, updating periodic reports, ICSR comparisons with company databases and studying the reporting patterns. The data is collected from each of its 110 member states which currently comprises to over 10 million ICSRs. About a hundred thousand ICSRs are added each year.

Guidances for statistics in regulatory affairs refers to specific documents or guidelines that provide instructions, recommendations, and standards pertaining to the application of statistical methodologies and practices within the regulatory framework of industries such as pharmaceuticals and medical devices. These guidances serve as a reference for statisticians, researchers, and professionals involved in designing, conducting, analyzing, and reporting studies and trials in compliance with regulatory requirements. These documents embody the prevailing perspectives of regulatory agencies on specific subjects. It is worth noting that in the United States, the term "Guidances" is used, while in Europe, the term "Guidelines" is employed.